p5E-161K enhancer-ETS-CORE-MUT
(Plasmid
#138372)
-
PurposeGateway compatible 5' entry clone contains human modified 161k enhancer sequence. with ETS binding sites mutated
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 138372 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepDONRP4-P1R
-
Backbone manufacturerThermoFisher
- Backbone size w/o insert (bp) 2643
- Total vector size (bp) 3634
-
Modifications to backbonenone
-
Vector typeGateway compatible
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert namehuman 161K human enhancer with ETS bind sites mutated
-
SpeciesH. sapiens (human)
-
Insert Size (bp)991
-
MutationETS factor binding sites mutated
- Promoter NONE
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer puc-M13 F
- 3′ sequencing primer puc-M13 R (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
This plasmid was constructed to functionally validate ETS factor binding sites in the 161K human enhancer.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
p5E-161K enhancer-ETS-CORE-MUT was a gift from Nathan Lawson (Addgene plasmid # 138372 ; http://n2t.net/addgene:138372 ; RRID:Addgene_138372) -
For your References section:
Genomic Characterization of Endothelial Enhancers Reveals a Multifunctional Role for NR2F2 in Regulation of Arteriovenous Gene Expression. Sissaoui S, Yu J, Yan A, Li R, Zhu LJ, Kucukural A, Yukselen O, Lawson ND. Circ Res. 2020 Feb 17. doi: 10.1161/CIRCRESAHA.119.316075. 10.1161/CIRCRESAHA.119.316075 PubMed 32065070